• Dudakova, Anna
• Weig, Michael
• Tangwattanachuleeporn, Marut
• Sasse, Christoph
• Spiess, Birgit
• Groß, Uwe
• Buchheidt, Dieter
• Bader, Oliver

Abstract

<jats:sec><jats:title>SUMMARY</jats:title><jats:p>The incidence of azole resistance in<jats:named-content content-type="genus-species">Aspergillus</jats:named-content>species has increased over the past years, most importantly for<jats:named-content content-type="genus-species">Aspergillus fumigatus</jats:named-content>. This is partially attributable to the global spread of only a few resistance alleles through the environment. Secondary resistance is a significant clinical concern, as invasive aspergillosis with drug-susceptible strains is already difficult to treat, and exclusion of azole-based antifungals from prophylaxis or first-line treatment of invasive aspergillosis in high-risk patients would dramatically limit drug choices, thus increasing mortality rates for immunocompromised patients. Management options for invasive aspergillosis caused by azole-resistant<jats:named-content content-type="genus-species">A. fumigatus</jats:named-content>strains were recently reevaluated by an international expert panel, which concluded that drug resistance testing of cultured isolates is highly indicated when antifungal therapy is intended. In geographical regions with a high environmental prevalence of azole-resistant strains, initial therapy should be guided by such analyses. More environmental and clinical screening studies are therefore needed to generate the local epidemiologic data if such measures are to be implemented on a sound basis. Here we propose a first workflow for evaluating isolates from screening studies, and we compile the MIC values correlating with individual amino acid substitutions in the products of<jats:italic>cyp51</jats:italic>genes for interpretation of DNA sequencing data, especially in the absence of cultured isolates.</jats:p></jats:sec>

Topics

• impedance spectroscopy
• size-exclusion chromatography